UNIVERSAL BIOSENSORS INC.
UBI - Quarterly Investor Update - Mr Mark Morrisson, CEO
Wed, 20 Aug 2008 10:00AM
Select a tab above to display more information
UNIVERSAL BIOSENSORS INC. (UBI)
ASX code: UBI
Website: http://www.universalbiosensors.com
Industry: Health Care Equipment & Services
Principal Activities:
The Company is a specialist medical diagnostics company focused on the development, manufacture and commercialisation of a range of in vitro diagnostic tests for point-of-care use.
Address:
1 Corporate Avenue
Rowville
VIC
Phone: (03) 9213 9000
Fax: (03) 9213 6490
Executives & Directors
Mr Andrew Denver , Chairman, Director
Mr Mark Morrisson , Director
Dr Colin Adam , Director
Mr Denis Hanley , Director
Mr Andrew Jane , Director
Mr Charles Kiefel , Director
Dr Elizabeth , Jane Wilson
Mr Salesh Balak , CFO
Mr Cameron Billingsley , Company Secretary
Company Podcasts
Company ASX Announcements
Company ASX announcements can be viewed on the ASX website.
Announcements from the preceding six months are shown below.
Please refer to the relevant stock exchange if any of the above information is incorrect
UNIVERSAL BIOSENSORS INC. (UBI) Events
| Company (Stock Code) | Date/Time | Event |
Timezone: Australia/NSW |
|---|---|---|---|
|
Wed, 3 Dec 2008 10:30AM |
UBI - Healthy Investment eConference - Mr Mark Morrisson, CEO |
     |
|
|
Wed, 20 Aug 2008 10:00AM |
UBI - Quarterly Investor Update - Mr Mark Morrisson, CEO |
|
|
|
Tue, 3 Jun 2008 09:30AM |
UBI - Quarterly Investor Update - Mr Mark Morrisson, CEO |
|
|
|
Fri, 29 Feb 2008 03:30PM |
UBI - Quarterly Investor Update - Mr Mark Morrisson, CEO |
|
|
|
Fri, 21 Dec 2007 10:00AM |
UBI - Operational Update - Mr Mark Morrisson, CEO |
|
|
|
Thu, 1 Nov 2007 10:00AM |
UBI - Investor Presentation - Mr Mark Morrisson, CEO |
|
|
Mon, 21 May 2007 01:30PM |
UBI - AGM Commentary - Mr Mark Morrisson, CEO |
|
| Thu, 14 May 2009 | Annual General Meeting | ||
| Thu, 9 Apr 2009 | Full Year Results | ||
| Wed, 6 Aug 2008 | Interim Results | ||
| Thu, 12 Jun 2008 10:00AM |
Annual General Meeting Level 12, 117 York Street, Sydney, NSW
|
||
| Thu, 9 Aug 2007 | Interim Results | ||
| Tue, 15 May 2007 09:00AM |
Annual General Meeting Level 12, 117 York Street Sydney NSW 2000
|
||
| Tue, 27 Feb 2007 11:00PM |
Full Year Results | ||
UNIVERSAL BIOSENSORS INC. (UBI)
| Presentation to Investor Conference | Fri, 4 Jul 2008 |
| Quarterly Investor Update | Tue, 3 Jun 2008 |
| Appendix 3Y | Mon, 19 May 2008 |
| Payment for Services | Mon, 12 May 2008 |
| Becoming a substantial holder from WIG | Thu, 8 May 2008 |
| Corporate Governance Statement | Wed, 7 May 2008 |
| Proxy Statement | Wed, 7 May 2008 |
| Annual Report | Wed, 7 May 2008 |
| Oak Ridge Conference Presentation | Wed, 7 May 2008 |
| Appendix 3B | Tue, 6 May 2008 |
Please note: This company appears on this website as a result of its listing on the Australian Securities Exchange. Boardroom Radio does not claim any association with any company listed on this site.
PRESENTATION BY MARK MORRISSON, CHIEF EXECUTIVE OFFICER OF UNIVERSAL BIOSENSORS, INC. (UBI)
“UBI - Quarterly Investor Update”
http://www.brr.com.au/event/49527
WEDNESDAY, AUGUST 20, 2008, 10:00 AM.
UBI Welcome to the Universal Biosensors Quarterly Investor Update. My name is Mark Morrisson and I am the CEO of Universal Biosensors. In this
10 presentation, I would like to describe the key activities of the Company for the quarter of April 2008 to June 2008.
Slide 2 summarizes the highlights of the quarter. In a highlight announced to the market, the Company negotiated a new services funding stream through
15 LifeScan for work associated with production scale-up activities of the blood glucose sensor for the diabetic market.
In other production-related news, we ordered five additional production machines which form the core of a second production line. These machines
20 duplicate the core of our existing production suite and like that suite will be used in the manufacture of blood glucose sensors.
Head count rose as we integrated a number of long-term LifeScan secondments into our teams. During secondment, LifeScan personnel are
25 based in Rowville but remain on LifeScan's payroll. In addition, new hires were added to our production, quality control and research teams.
Our management system was audited during our annual inspection by TUV SUD, our notified body. We passed this audit.
30
Slide 3 summarizes current progress in operations. Across the quarter, activities associated with production development and scale up accelerated and we are extremely pleased by the significant and increasing LifeScan engagement with the Company. As noted in the highlights, we are
35 strategically embedding key LifeScan talent into a number of Universal Biosensors work teams. The cost of the secondment is paid for by LifeScan even though these workers are based in Rowville.
We were also pleased to announce an additional agreement for the provision
40 of services to LifeScan which we are starting to receive revenue. These new contributions in cash and kind are additional to those described in the Master Services and Supply Agreement concluded late last year.
Across the quarter, Universal Biosensors ordered five additional pieces of
45 new manufacturing equipment. These pieces duplicate the core manufacturing pieces already in place on the Universal Biosensors factory floor and are intended for use in manufacturing blood glucose sensors. The first two of these five new pieces are slated for delivery later this year.
Our current regulatory and quality activities are summarized in Slide 4. Our notified body, TUV SUD, conducted the first audit in our new building of our quality management system which we passed successfully.
5 The preparation of regulatory dossiers continues. This is an important part of the blood glucose product program since successful review and approval of submissions triggers milestone payments for Universal Biosensors. Under the Master Services and Supply Agreement, there are three such milestone payments, one associated with each of three territories.
10
In the meantime, we continue to validate all aspects of the development and manufacturing process.
Slide 5 shows that currently we just have under 157 million shares on issue.
15 The number of issued and outstanding options is approximately $6.2 million. Universal Biosensors financial year corresponds with the calendar year.
Slide 6 shows revenue for services from the new LifeScan funding stream of just over $1.2 million and income from research and development during the
20 half year of just over $519,000. Operating expenses for the half year were approximately A$6.6 million and show an increase over the corresponding period last year, reflecting increased path to market activity subsequent to the signing of the Master Services and Supply Agreement and an acceleration of our R&D efforts as we apply some of the funds of our December 2007 capital
25 raising. Nonetheless, our net loss corresponds roughly to that of the same period last year.
As shown in Slide 7, we have approximately A$35.6 million held in cash and cash equivalents with over $19 million worth of plant and equipment. With
30 about $4.4 million worth of liabilities, this equates to approximately $56 million worth of shareholders equity.
Further details are given in Slide 8.
35 Finally, with Slide 9, I would like to leave you all with the key messages of last quarter. One is of the significant and increased support of our partner for the blood glucose product. We have always been pleased with the solid support shown by our partner towards the potential of our technology. Now, with the product in the pre-launch phase, the relationship continues to strengthen as
40 evidenced by new commitments beyond those described in last year's Master Services and Supply Agreement.
Finally, and not least, we continue to make good progress with our other development projects. I look forward to delivering more news on our progress
45 next quarter. Thank you for listening.
PRESENTATION CONCLUDED
Contact brr@brr.com.au for more information
DISCLAIMER: Transcripts made available by Boardroomradio.com is a free service whereby the transcripts are created by one or more third party contractors without any involvement or oversight by Boardroomradio.com or the respective company, firm, partnership or individual that is being transcribed. Boardroomradio.com and its contractors, client companies, firms, partnerships and guest speakers (paid or otherwise) do not invite reliance upon, nor accept responsibility for, the information they provide. Boardroomradio.com makes every effort to provide a high quality service. However, neither Boardroomradio.com, its transcript providers, nor the providers of any other written or oral data made available on the Boardoomradio.com site (and its partner sites) give any guarantees, undertakings or warranties concerning the accuracy, completeness or up-to-date nature of the information provided. Users should confirm information from another source if it is of sufficient importance for them to do so. Boardroomradio.com, its directors and employees do not accept any liability for the results of any actions taken or not taken on the basis of information in this site, or for any negligent misstatements, errors or omissions.
